Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

Executive Summary

• Rapid Dose Therapeutics Corp. received a granted Indian patent (No. IN 582202) for its QuickStrip™ Nicotine Bilayer Oral Film, covering formulation and manufacturing processes.
• The grant advances the company’s global IP strategy that began with a PCT filing in May 2025, extending potential protection to up to 158 jurisdictions worldwide.
• The milestone strengthens Rapid Dose’s negotiating position for commercial agreements with major nicotine companies and supports its expansion into the fast‑growing oral nicotine market (projected $38.9 bn by 2033).

Key Details

• Patent Information: Title – “Nicotine Bilayer Oral Film and Process for Preparation Thereof”; Indian Patent Number IN 582202; based on Application No. IN 202441055689 filed July 22, 2024 under the PCT framework.
• Scope of Protection: Covers bilayer oral thin‑film technology for controlled nicotine delivery, including proprietary formulation and manufacturing processes enabling rapid absorption and discreet administration.
• Global IP Strategy: Initial PCT filing (May 2025) seeks protection in up to 158 jurisdictions; Rapid Dose plans to register the granted Indian patent in additional jurisdictions to create commercial opportunities.
• Market Context: Global modern oral nicotine market valued at ~US$7.96 bn in 2024; projected to reach US$38.89 bn by 2033, CAGR ≈19%. Growth driven by demand for smoke‑free nicotine alternatives and innovation in delivery systems.
• Strategic Importance of India: Large consumer base and major pharmaceutical manufacturing hub; patent enhances positioning for commercial discussions with a “major global nicotine company” engaged for nearly three years.
• Quote (SVP Business Development & Co‑Inventor): “This patent grant is clear evidence that RDT is delivering on the strategy we communicated to investors… a key milestone for systematically securing key jurisdictions and strengthening our global negotiating position.”
• Future Outlook: Company intends to leverage the granted patent to advance commercial agreements, protect shareholder value, and expand globally with the QuickStrip™ platform for nicotine, pharmaceuticals, nutraceuticals, and vaccines.

Notable Quotes

“This patent grant is clear evidence that RDT is delivering on the strategy we communicated to investors,” said Jason Lewis, SVP Business Development and co‑inventor.
“The PCT patent issuance… is a key milestone for systematically securing key jurisdictions and strengthening our global negotiating position.”